S&P 500
7,718.94
-86.51
-1.11%
Dow
51,621.48
-48.62
-0.09%
Nasdaq
26,692.87
-511.51
-1.88%
NYSE Composite
23,865.42
-119.58
-0.50%
Russell 2000
2,729.53
-53.84
-1.93%
VIX
16.87
+1.60
+10.48%
NRIX · Nurix Therapeutics, Inc. Common stock
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Nurix Therapeutics Inc (NRIX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$23.66
+1.55
(+6.99%)
● At close: October 14 at 4:00:00 PM EDT
$23.67
+0.00
(+0.00%)
After-Hours:
4:00:53 PM EDT
DAY'S RANGE
$23.66
$21.47
$24.01
52-WEEK RANGE
$23.66
$9.00
$28.23
What's happening
- NRIX is up 6.99% today, trading at $23.66. — Live quote
- Volume today (121,653) is well below its 3-month average of 1,913,800. (Finnhub fundamentals)
- Last quarter's EPS missed estimates: $-0.81 actual vs. $-0.73 estimated (-10.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 12
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (21 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NRIX
+16.66%
vs S&P 500
+2.57%
1-YEAR RETURN
NRIX
+127.67%
vs S&P 500
+110.34%
6-MONTH RETURN
NRIX
+36.27%
3-MONTH RETURN
NRIX
-3.70%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.81
Est. $-0.73
MISS -10.8%
2026-04-26 (Q1 2026)
$-0.79
Est. $-0.77
MISS -2.7%
2026-01-26 (Q4 2025)
$-0.82
Est. $-0.89
BEAT +7.7%
2025-10-26 (Q3 2025)
$-1.03
Est. $-0.86
MISS -20.0%
Valuation Measures & Ratios
Enterprise Value4$2.27B
Forward P/E511.47
PEG Ratio6—
Price / Sales (TTM1)63.51
Price / Book74.47
EV4 / Revenue61.67
EV4 / EBITDA—
Profit Margin-928.44%
Operating Margin-982.37%
Return on Equity (ROE8)-76.09%
Return on Assets (ROA9)-57.32%
Avg Volume (3M)1,913,800
Quarterly history (5 periods)
| Measure | Aug '26 | May '26 | Feb '26 | Aug '25 | May '25 |
|---|---|---|---|---|---|
| Market cap | $2.99B | $1.96B | $1.76B | $783.2M | $886.4M |
| P/E | 10.44 | -6.40 | -6.45 | -3.33 | -4.59 |
| Price/Sales | 4.30 | 29.17 | 23.01 | 9.44 | 10.17 |
| Price/Book | 3.09 | 4.87 | 3.67 | 2.10 | 1.98 |
| EV/Revenue | 3.27 | 28.16 | 22.08 | 8.49 | 9.20 |
| ROE | 29.61% | -76.15% | -56.85% | -63.18% | -43.19% |
| ROA | 23.98% | -57.25% | -42.98% | -45.02% | -32.68% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short17,657,588
Change from Prior Settlement-1.78%
% of Float—
Days to Cover (Short Ratio)9.94
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +127.7%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -79.5% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -928.4%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NRIX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Aug '26 | May '26 | Feb '26 | Aug '25 | May '25 | Feb '25 | Aug '24 | May '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $673.1M | $9.0M | $6.3M | $7.9M | $44.1M | $18.5M | $12.6M | $12.1M |
| Operating income | $559.5M | -$94.2M | -$92.5M | -$91.4M | -$48.3M | -$62.9M | -$54.6M | -$48.5M |
| Net income | $549.8M | -$89.5M | -$87.2M | -$86.4M | -$43.5M | -$56.4M | -$49.0M | -$44.5M |
| EPS (diluted) | $4.73 | $-0.81 | $-0.79 | $-1.03 | $-0.52 | $-0.67 | $-0.67 | $-0.71 |
| EPS (basic) | $4.93 | $-0.81 | $-0.79 | $-1.03 | $-0.52 | $-0.67 | $-0.67 | $-0.71 |
| Operating margin | $83 | -$1.0K | -$1.5K | -$1.2K | -$110 | -$341 | -$434 | -$401 |
| Net margin | $82 | -$990 | -$1.4K | -$1.1K | -$99 | -$305 | -$389 | -$368 |
Balance sheet
| Line item | Aug '26 | May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.20B | $535.5M | $636.1M | $688.1M | $522.5M | $591.6M | $615.0M | $669.3M |
| Total liabilities | $227.0M | $132.9M | $155.2M | $149.4M | $150.2M | $144.0M | $134.1M | $142.3M |
| Stockholders' equity | $968.3M | $402.6M | $480.9M | $538.7M | $372.3M | $447.6M | $480.9M | $527.0M |
| Total current assets | $1.10B | $456.5M | $554.4M | $606.8M | $440.6M | $515.3M | $563.7M | $619.4M |
| Total current liabilities | $130.7M | $72.0M | $92.2M | $86.5M | $82.3M | $75.6M | $90.0M | $95.9M |
| Cash & equivalents | $720.2M | $67.7M | $71.2M | $247.0M | $78.4M | $84.3M | $75.9M | $110.0M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $20.0M | — | — | $0 | — | $19.0M | — | $0 |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $19.4M | $20.0M | $21.7M | $22.5M | $20.5M | $18.8M | $18.4M | $17.8M |
| Other non-current assets | $8.0M | $8.0M | $7.4M | $7.3M | $7.4M | $6.3M | $5.6M | $3.2M |
| Accounts payable | $33.0M | $12.2M | $10.3M | $11.2M | $8.6M | $6.0M | $8.4M | $11.5M |
| Deferred revenue (current) | $8.6M | $13.3M | $18.8M | $17.6M | $26.0M | $27.4M | $30.6M | $38.4M |
| Other current liabilities | $1.5M | $1.3M | $1.9M | $2.1M | $1.7M | $1.0M | $2.7M | $2.3M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $109.0K | $104.0K | $103.0K | $102.0K | $77.0K | $76.0K | $76.0K | $76.0K |
| Retained earnings | -$630.1M | -$1.18B | -$1.09B | -$1.00B | -$925.0M | -$838.6M | -$795.1M | -$738.8M |
| Accumulated other comprehensive income (loss) | -$210.0K | -$145.0K | $56.0K | $105.0K | $119.0K | -$20.0K | $226.0K | $150.0K |
Cash flow
| Line item | Aug '26 | May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $615.6M | -$96.6M | -$71.9M | -$67.8M | -$57.4M | -$63.2M | -$61.1M | -$48.8M |
| Investing cash flow | $31.6M | $93.0M | -$123.8M | $346.0K | $50.5M | $71.5M | $25.5M | -$140.8M |
| Financing cash flow | $5.2M | $66.0K | $20.0M | $236.0M | $1.2M | $6.0K | $1.5M | $200.5M |
| Free cash flow | $614.2M | -$98.5M | -$73.0M | -$73.0M | -$60.1M | -$65.8M | -$64.6M | -$50.9M |
| Capital expenditures | $1.4M | $1.9M | $1.0M | $5.1M | $2.7M | $2.7M | $3.5M | $2.1M |
| Share-based compensation | $10.8M | $11.4M | $9.4M | $9.1M | $9.8M | $10.4M | $8.7M | $8.5M |
| Change in accounts receivable | $20.0M | $0 | — | — | -$19.0M | $19.0M | — | $0 |
| Change in accounts payable | $20.6M | $1.9M | -$461.0K | $3.0M | $2.2M | -$2.7M | -$3.2M | $7.6M |
| Purchases of investments | $149.4M | $24.6M | $255.9M | $174.3M | $103.0M | $68.2M | $110.2M | $298.2M |
Income statement
| Line item | Nov '25 | Nov '24 | Nov '23 | Nov '22 | Nov '21 |
|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | — |
| Operating income | -$285.7M | -$213.0M | -$155.1M | -$183.9M | -$117.9M |
| Net income | -$264.5M | -$193.6M | -$143.9M | -$180.4M | -$117.2M |
| EPS (diluted) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 |
| EPS (basic) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 |
| Operating margin | -$340 | -$391 | -$201 | -$476 | — |
| Net margin | -$315 | -$355 | -$187 | -$467 | — |
Balance sheet
| Line item | Nov '25 | Nov '24 | Nov '23 | Nov '22 | Nov '21 |
|---|---|---|---|---|---|
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M |
| Total liabilities | $149.4M | $142.3M | $155.1M | $113.1M | $134.5M |
| Stockholders' equity | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M |
| Total current assets | $606.8M | $619.4M | $295.5M | $318.4M | $311.1M |
| Total current liabilities | $86.5M | $95.9M | $87.0M | $70.7M | $66.3M |
| Cash & equivalents | $247.0M | $110.0M | $54.6M | $64.5M | $80.5M |
| Property, plant & equipment | $22.5M | $17.8M | $16.8M | $17.2M | $11.3M |
| Other non-current assets | $7.3M | $3.2M | $3.8M | $4.0M | $2.8M |
| Accounts payable | $11.2M | $11.5M | $6.4M | $5.1M | $6.7M |
| Deferred revenue (current) | $17.6M | $38.4M | $48.1M | $37.6M | $41.2M |
| Other current liabilities | $2.1M | $2.3M | $751.0K | $1.5M | $659.0K |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $102.0K | $76.0K | $49.0K | $47.0K | $45.0K |
| Retained earnings | -$1.00B | -$738.8M | -$545.2M | -$401.3M | -$220.9M |
| Accumulated other comprehensive income (loss) | $105.0K | $150.0K | -$655.0K | -$4.3M | -$608.0K |
Cash flow
| Line item | Nov '25 | Nov '24 | Nov '23 | Nov '22 | Nov '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$249.5M | -$172.6M | -$81.4M | -$159.8M | -$84.4M |
| Investing cash flow | $147.9M | -$257.7M | $68.3M | $27.2M | -$108.3M |
| Financing cash flow | $238.6M | $485.7M | $3.2M | $117.2M | $153.9M |
| Free cash flow | -$263.5M | -$181.9M | -$89.8M | -$172.1M | -$90.0M |
| Capital expenditures | $14.0M | $9.3M | $8.4M | $12.2M | $5.7M |
| Share-based compensation | $38.0M | $33.9M | $33.7M | $28.1M | $15.8M |
| Change in accounts receivable | — | $0 | $0 | -$6.0M | $6.0M |
| Change in accounts payable | -$630.0K | $5.2M | $1.6M | $85.0K | $1.6M |
| Purchases of investments | $455.7M | $708.0M | $246.3M | $239.4M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NRIX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-04 to 2026-10-14
Recent transactions
- Insiders have net sold 151,652 shares over the last 182 days, across 0 purchases and 21 sales.
- Most recent: GREGORY JULIA P (Director) — Option exercise of 22,583 shares on 2026-10-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)151,652 sh(21 txns)
Net Shares-151,652
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| GREGORY JULIA P | Director | Option exercise | 2026-10-14 | 22,583 |
| Ring Christine | Chief Legal Officer | Option exercise | 2026-10-02 | 5,786 |
| Hansen Gwenn | Chief Scientific Officer | Option exercise | 2026-09-01 | 1,452 |
| van Houte Hans | Chief Financial Officer | Open market sale | 2026-08-04 | 1,794 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-14 | GREGORY JULIA P | Director | Option exercise | 22,583 | $1.86 |
| 2026-10-14 | GREGORY JULIA P | Director | Open market sale | 22,583 | $23.40 |
| 2026-10-02 | Ring Christine | Chief Legal Officer | Option exercise | 5,786 | $8.72 |
| 2026-10-02 | Ring Christine | Chief Legal Officer | Open market sale | 5,786 | $23.19 |
| 2026-09-02 | Ring Christine | Chief Legal Officer | Option exercise | 5,787 | $8.72 |
| 2026-09-02 | Ring Christine | Chief Legal Officer | Open market sale | 5,387 | $25.69 |
| 2026-09-02 | Ring Christine | Chief Legal Officer | Open market sale | 400 | $26.64 |
| 2026-09-01 | Hansen Gwenn | Chief Scientific Officer | Option exercise | 1,452 | $1.86 |
| 2026-09-01 | Hansen Gwenn | Chief Scientific Officer | Open market sale | 1,452 | $25.47 |
| 2026-08-05 | Hansen Gwenn | Chief Scientific Officer | Option exercise | 4,356 | $1.86 |
| 2026-08-05 | Hansen Gwenn | Chief Scientific Officer | Open market sale | 4,356 | $25.00 |
| 2026-08-04 | Hansen Gwenn | Chief Scientific Officer | Open market sale | 1,500 | $23.87 |
| 2026-08-04 | Hansen Gwenn | Chief Scientific Officer | Open market sale | 2,611 | $24.64 |
| 2026-08-04 | van Houte Hans | Chief Financial Officer | Open market sale | 1,794 | $23.89 |
| 2026-08-04 | van Houte Hans | Chief Financial Officer | Open market sale | 2,967 | $24.65 |
| 2026-08-03 | Ring Christine | Chief Legal Officer | Option exercise | 5,787 | $8.72 |
| 2026-08-03 | Ring Christine | Chief Legal Officer | Open market sale | 16,589 | $23.05 |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Option exercise | 3,750 | $0.00 |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Option exercise | 2,858 | $0.00 |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Option exercise | 3,572 | $0.00 |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Open market sale | 2,845 | $23.38 |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Option exercise | 3,750 | $0.00 |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Option exercise | 2,858 | $0.00 |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Option exercise | 3,572 | $0.00 |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Open market sale | 3,847 | $23.38 |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Option exercise | 3,750 | $0.00 |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Option exercise | 2,858 | $0.00 |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Option exercise | 3,572 | $0.00 |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Open market sale | 3,847 | $23.38 |
| 2026-07-02 | Ring Christine | Chief Legal Officer | Option exercise | 5,221 | $1.86 |
| 2026-07-02 | Ring Christine | Chief Legal Officer | Option exercise | 5,787 | $8.72 |
| 2026-07-02 | Ring Christine | Chief Legal Officer | Open market sale | 11,008 | $23.56 |
| 2026-06-25 | Hansen Gwenn | Chief Scientific Officer | Open market sale | 5,394 | $20.00 |
| 2026-06-25 | Ring Christine | Chief Legal Officer | Option exercise | 13,333 | $7.26 |
| 2026-06-25 | Ring Christine | Chief Legal Officer | Option exercise | 15,602 | $8.72 |
| 2026-06-25 | Ring Christine | Chief Legal Officer | Open market sale | 28,935 | $20.06 |
| 2026-06-02 | Ring Christine | Chief Legal Officer | Option exercise | 3,422 | $1.86 |
| 2026-06-02 | Ring Christine | Chief Legal Officer | Open market sale | 8,148 | $16.60 |
| 2026-05-05 | van Houte Hans | Chief Financial Officer | Open market sale | 13,473 | $16.58 |
| 2026-05-05 | van Houte Hans | Chief Financial Officer | Open market sale | 582 | $17.18 |
| 2026-05-04 | Ring Christine | Chief Legal Officer | Open market sale | 8,148 | $16.96 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-14 21:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-13 | 10-Q | 2026-08-31 | View on SEC.gov → |
| 2026-10-13 | 8-K | 2026-10-12 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-05 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-04 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-04 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-07-30 | 4 | 2026-07-30 | View on SEC.gov → |
| 2026-07-30 | 4 | 2026-07-30 | View on SEC.gov → |
Recent news
Headlines about NRIX (Nurix Therapeutics, Inc. Common stock). Links open the publisher — we don’t host full articles.
-
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Director Sells 22,583 Shares of Company Stock
MarketBeat · 2026-10-14 -
A director proposes selling 22,583 Nurix Therapeutics (Nasdaq: NRIX) shares acquired by exercising options.
Stock Titan · 2026-10-14 -
Nurix Therapeutics (NASDAQ:NRIX) Shares Climb 4.1% After Analyst Upgrade
MarketBeat · 2026-10-14 -
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
SeekingAlpha · 2026-10-14 -
NRIX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing
GuruFocus · 2026-10-14 -
Nurix Therapeutics, Inc. (NRIX) Stock Price, News, Quote & History
Yahoo Finance · 2026-10-13 -
NRIX Maintained by RBC Capital -- Price Target Lowered to $35
GuruFocus · 2026-10-13 -
NRIX Maintained by Oppenheimer -- Price Target Raised to $32
GuruFocus · 2026-10-13
No headlines in this category right now — try “All”.